| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/10/2001 | WO2001032173A1 Kainic acid neurocytotoxicity inhibitors |
| 05/10/2001 | WO2001032171A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 05/10/2001 | WO2001032169A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | WO2001032168A1 Method of treating benign forgetfulness |
| 05/10/2001 | WO2001032167A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | WO2001032165A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | WO2001032161A2 Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032148A1 Controlled release hydrocodone formulations |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001016304A3 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |
| 05/10/2001 | WO2001012175A8 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/10/2001 | WO2001005393A3 Method for treating chronic pain using mek inhibitors |
| 05/10/2001 | WO2001004122A3 New 2,3-benzodiazepine derivatives |
| 05/10/2001 | WO2000077035A3 Novel potassium channels and genes encoding these potassium channels |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO2000061170A3 Novel medical use of alpha-1-acidic glycoprotein (aag or orosomucoid) |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | US20010001100 For treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | CA2390180A1 Choline transporter like (ctl) membrane proteins involved in choline transport |
| 05/10/2001 | CA2389973A1 Method of treating amyloid beta precursor disorders |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389672A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389645A1 Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
| 05/10/2001 | CA2389623A1 Method of treating benign forgetfulness |
| 05/10/2001 | CA2389439A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389293A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | CA2389259A1 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists |
| 05/10/2001 | CA2389234A1 2-cyclohexyl benzimidazole nmda/nr2b antagonists |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2389226A1 1,4 substituted piperidinyl nmda/nr2b antagonists |
| 05/10/2001 | CA2389184A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 05/10/2001 | CA2389182A1 2-aza-bicyclo¬2.2.2|octane nmda/nr2b antagonists |
| 05/10/2001 | CA2388822A1 27 human secreted proteins |
| 05/10/2001 | CA2388202A1 Polymorphic form of a tachykinin receptor antagonist |
| 05/10/2001 | CA2388171A1 8-aza-bicyclo[3.2.1]octane nmda/nr2b antagonists |
| 05/10/2001 | CA2387801A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | CA2387785A1 Human transferase molecules |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387745A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | CA2387741A1 Positive modulators of nicotinic receptor agonists |
| 05/10/2001 | CA2387660A1 Diaryl-enynes as glycine transport inhibitors |
| 05/10/2001 | CA2387613A1 Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them |
| 05/10/2001 | CA2387261A1 25 human secreted proteins |
| 05/10/2001 | CA2387136A1 26 human secreted proteins |
| 05/10/2001 | CA2387135A1 Polymorphic forms of sertraline hydrochloride |
| 05/10/2001 | CA2386938A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 05/10/2001 | CA2386641A1 32 human secreted proteins |
| 05/10/2001 | CA2385928A1 Agonists specific for the peripheral cannabinoid receptor |
| 05/10/2001 | CA2324813A1 Combination treatment for depression and anxiety |
| 05/09/2001 | EP1097924A1 4-hydroxy-4-phenylpiperidine derivatives having -opioid agonist activity and pharmaceuticals containing the same |
| 05/09/2001 | EP1097921A1 Phenylhydrazines |
| 05/09/2001 | EP1097719A1 NEP inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097718A1 NPY antagonists for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097707A1 Treatment of female sexual dysfunction |
| 05/09/2001 | EP1097706A1 Phosphodiesterase inhibitors for the treatment of female sexual dysfunction |
| 05/09/2001 | EP1097698A2 Utilization of derivatives of tetrahydropyridines (or 4-hydroxypiperidines)-butylazols in the preparation of a medicament for the treatment of pain |
| 05/09/2001 | EP1097382A2 Imidazoline receptor binding compounds |
| 05/09/2001 | EP1097203A1 Human presenilin-associated protein |
| 05/09/2001 | EP1097201A1 Snurpotine i human m 3?g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 05/09/2001 | EP1097168A2 Compounds and methods for modulating cadherin-mediated functions |
| 05/09/2001 | EP1097167A2 Neurotrophic growth factor |
| 05/09/2001 | EP1097149A1 Bicyclohexane derivatives |
| 05/09/2001 | EP1097139A1 Quinoline derivatives |
| 05/09/2001 | EP1097137A1 N-substituted naphthalene carboxamides as neurokinin-receptor antagonists |
| 05/09/2001 | EP1096946A2 Delta cleavage products and methods based thereon |
| 05/09/2001 | EP1096936A1 Treatment of dyskinesia |
| 05/09/2001 | EP1096935A1 Medicinal product and method for treatment and prevention of dyskinesia |
| 05/09/2001 | EP1096932A2 Antihypertensive combination of valsartan and calcium channel blocker |
| 05/09/2001 | EP1096931A2 Use of (s) (-)-amisulpride for the manufacture of a medicament for the treatment of schizophrenia |
| 05/09/2001 | EP1096927A1 Composition for treatment of stress |
| 05/09/2001 | EP1096926A2 Methods and compounds for treating depression |
| 05/09/2001 | EP1033131A4 Composition of ingredients for a beverage having a delayed aversion effect |
| 05/09/2001 | CN1294595A Hydrophobically-modified protein compsns, and methods |
| 05/09/2001 | CN1294590A Method of 3-substituted adenines via 2-thioxanthines |
| 05/09/2001 | CN1294513A Pharmaceutically active morpholinol |
| 05/09/2001 | CN1294512A Paroxetine compsns. |
| 05/09/2001 | CN1294193A Human Fb65L2-2 protein and polynucleotide sequence to code it |
| 05/09/2001 | CN1294120A Process for preparing optical-purity fluoxetine |
| 05/09/2001 | CN1294016A Injection for giving up addiction |
| 05/09/2001 | CN1294004A Chinese patent medicine for taking care of brain health |
| 05/09/2001 | CN1294002A Chinese medicine for treating neuropathy |
| 05/09/2001 | CN1293990A Medicine 'Changlongdan' |
| 05/09/2001 | CN1293980A Medicine for quickly dropping drug |
| 05/09/2001 | CN1293979A Medicine for quickly dropping drug |
| 05/09/2001 | CN1293966A Health-care product for improving sleep |
| 05/09/2001 | CN1293965A Natural drug-dropping medicine |
| 05/09/2001 | CN1065536C Process and crystal form of 2-methyl-thieno-benzodiazepine |
| 05/09/2001 | CN1065535C Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders |
| 05/09/2001 | CN1065429C Alpha-cyclic tetrhydro niacinamide monomucleotide or its probody alpha-cyclic tetrahydro niacinamide adenosin dinucleotide and its prepn. process |
| 05/08/2001 | US6229026 Reacting an isobenzofuran derivative with grignard reagents 4-halogen-fluorophenyl and 3-halogen-n,n-dimethylpropylamine; causing ring-closure of the product and conversion to 5-cyano derivative |
| 05/08/2001 | US6229025 Process for alkylating hindered sulfonamides |
| 05/08/2001 | US6229013 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 05/08/2001 | US6228893 Treating dementia |